H.R. Kim

机构：Yonsei University, Severance Hospital, Samsung Medical Center

发表论文 8 篇 · 总被引 21 次 · h-index 3

代表论文

• EP08.01-073 AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC (2022 · Journal of Thoracic Oncology · 被引 6)
• 123TiP: TROPION-Lung14: A phase III study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) (2025 · Journal of Thoracic Oncology · 被引 5)
• MA13.11 Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial (2023 · Journal of Thoracic Oncology · 被引 3)
• 148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) (2022 · Immuno-Oncology Technology · 被引 3)
• LBA105 A phase II, open-label, single-arm, multi-center study of rivoceranib in patients with metastatic thymic epithelial tumor, KCSG LU23-09 (THRIVE) (2025 · Annals of Oncology · 被引 1)
• OP01-5 Efficacy and safety of larotrectinib in NTRK fusion-positive solid tumor patients: A multi-center retrospective study (2025 · ESMO Open · 被引 1)